Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions – BioSpace

Pathos AI has announced strategic partnerships with Bristol Myers Squibb and Tempus AI to advance artificial intelligence-driven drug development, with an initial focus on Alzheimer’s disease and other neurological conditions. The collaboration aims to leverage AI technology to accelerate the drug development process in these therapeutic areas.

Read Full Article →